https://doi.org/10.4081/hmr.v2i13.491

Optimizing denileukin diftitox (Ontak®) therapy

Vol. 2 No. 13: It’s time to take care of T-Cell Lymphomas Bologna, Italy, 22-24 October 2006
Published: June 10, 2009
Abstract Views: 176
PDF: 729
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M Duvic
support@pagepress.org
Denileukin diftitox (Ontak®) is a genetically engineered recombinant fusion protein composed of the full length interleukin 2 and the catalytic domain of diphtheria toxin. As such, Ontak or formerly DAB389IL2 is the first targeted therapy of the fusion toxin class to be approved. This therapy has broad applicability for targeting any ligand receptor that internalizes after binding. Ontak was first introduced in 1992, and tested for safety and activity in autoimmune disease (rheumatoid arthritis, psoriasis), type I diabetes, HIV, and hematologic malignancies (Strom TB 1993).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Duvic, M. (2009). Optimizing denileukin diftitox (Ontak®) therapy. Hematology Meeting Reports (formerly Haematologica Reports), 2(13). https://doi.org/10.4081/hmr.v2i13.491
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).